Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women of age 18-65 years (Argentina the minimum age will be 24 years of age)~* Patients randomized in parent study who complete CN162-006 and CN162-007 who consent to enter the rollover study.~* Patient not randomized in parent study that meet inadequate response criteria~Exclusion Criteria:~* Patients who represent a significant risk of committing suicide based on the clinical judgment of the investigator, history or routine psychiatric status exam.~* Patients with a Cardiovascular System Organ Class adverse event(s) occurring in parent study (CN162-006 or CN162-007), that in the investigators judgment is clinically significant and would impact safety of the subject in the current study \[including but not limited to left bundle branch block, or prolonged QT interval corrected (QTc)\].~* In addition, patients should be excluded if they have any laboratory test, vital sign, electrocardiogram (ECG) or clinical findings that in the investigator's judgment is clinically significantly abnormal and could impact the safety of the patient or the interpretation of study assessments in the current study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Placebo + BMS-820836 (0.5 mg/day) (Type: EXPERIMENTAL): None
- Arm 2: Placebo + BMS-820836 (1 mg/day) (Type: EXPERIMENTAL): None
- Arm 3: Placebo + BMS-820836 (2 mg/day) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).